From The Cancer Chronicles #30
© Dec. 1995 by Ralph W. Moss, Ph.D.

On November 22, 1995 we received the following letter:

"To the Editor:

"I need your advice. From January, 1995 to September 1995 I was taking a non-toxic cancer drug called LK 200. It had no side effects and kept my tumor (colon cancer) under control and even seemed to shrink it. This was an experimental drug which came from the Bahamas. Suddenly, with no warning, I was cut off from my three times a week dosage with no explanation. It just wasnt being shipped, and no one would answer the phone. I was very upset.

"From what I can piece together, the FDA closed down the clinic and is threatening to sue the developer and distributor of LK200. My feeling is that the FDA should do their busines with the utmost regard for us patients. Surely there was a list of those of us taking the medicine. Surely they could have dealt with us 50 or 100 people--U.S. citizens, by the way--individually and kept the responders on the medicine. There has to be a way to punish [alleged, ed.] wrongdoing without also punishing people who are already living under a "terminal" diagnosis.

"My feeling is that the FDA should do their busines with the utmost regard for us patients.

"When I tried to call the FDA after this happened, they said they had never heard of LK 200. Are they covering up? Is this an example of how our government helps the huge drug companies squash non-toxic cancer therapies? I am deeply concerned.

"I need a lawyer to talk to about a class action suit against the FDA. There were some of us responding to the LK200 and the FDA has taken away our lifeline. As you can imagine, I feel a lot of urgency about this. Our government cant get away with killing us.


"Sara Stone-Alston, 2345 N. 133rd, Seattle, WA 98133"

Editor's note: We have been closely following the LK200 story since its inception over two years ago. The Office of Alternative Medicine (OAM) even sent representatives to Mexico for a press conference on this topic a year ago. Through these contacts we learned many interesting facts about the product.

The name LK200 referred to lymphokine-200, the putative number of such messenger proteins in the human body.

LK200 was developed by eminent scientists at Tufts University Medical Center in Boston, and marketed by a company called Private Biologicals, Inc. in Atlanta, Georgia. The treatment was then administered over a several week period at a hospital in Freeport, Bahamas, and another in Monterrey, Mexico.

By extracting a certain portion of the blood that was rich in normal lymphokines these scientists were apparently able to restore normal immune functioning to some cancer patients. The treatment was entirely non-toxic.

The company was quite scrupulous in their record keeping, at least compared to some other offshore clinics one could mention. They provided me with detailed summaries on their first 50 cases. In this group, there were seven complete remissions, including a woman with advanced breast cancer, a case of carcinoid, a case of advanced melanoma, etc.

Given the extent of these peoples disease these were extraordinary outcomes. There was also some stabilization of disease and/or significant pain relief in others.

Private Biologicals was enthusiastically gathering data for a clinical trial of LK-200, which was set to occur in multiple myeloma, a kind of cancer for which there are very few good treatments.

Then, just as Ms. Stone-Alston relates, someone lowered the boom. I received a frantic phone call from Tom Hodge, Ph.D., one of the companys officers, informing me that the day before FDA agents had raided the company's Massachusetts production facility. Initially, he said, several FDA agents had entered the plant in an exceptionally friendly manner. They obtained various samples of materials, left, and then re-emerged 15 minutes later with a warrant. Tom felt this was entrapment.

Since I had known him, every conversation with Tom had focussed on how careful they were trying to be to satisfy every requirement of the FDA! Now this! I suggested that he take this extraordinary story to the media and to friends in Congress. After all, he seemed to have behind him a considerable amount of good data, prestigious supporters, and a core group of satisfied patients.

However, despite verbal agreement, I sensed fear and doubt. I went on a trip and when I came back I called him. His business phone was now disconnected, with no forwarding number! I called the clinic in the Bahamas where the medicine had been dispensed. The doctor knew no more than I did. I left a message on the various personal answer machines. No response. And most tragically, the patients who had entrusted their lives to the treatment, were left high and dry. And that is how a promising cancer treatment bit the dust.

articles on
freedom of choice
Burton hearings

Ralph W. Moss, Ph.D. is director of the The Moss Reports for cancer patients. Dr. Moss is the author of eleven books and three documentaries on cancer-related topics. He is or has been an advisor on alternative cancer treatments to the National Institutes of Health, the National Cancer Institute, the American Urological Association, Columbia University, the University of Texas, the Susan G. Komen Foundation and the German Society of Oncology. He wrote the first article on alternative medicine for the Encyclopedia Britannica yearbook. He is listed in Marquis Who's Who in America, Who's Who in the World, Who's Who in the East, and Who's Who in Entertainment (as a film documentarian). This Web site does not advocate any particular treatment for cancer. We urge you to always seek competent medical advice for all health problems, especially cancer. Before consulting our site please read our full Disclaimer statement.

home - moss reports - books - - contact - order - news
members - chronicles - faq - free email newsletter